17-7-1　ⓔ文献

  1. 三谷絹子：がん遺伝子/がん抑制遺伝子と発がん．カラーテキスト 血液病学 (木崎昌弘編)，中外医学社，2013; 33–40.

  2. Knudson AG: Mutation and cancer statistical study of retinoblastoma. Proc Natl Acad Sci USA, 1971; 68: 820–823.

  3. Pallagatti A, Boultwood J: The molecular pathogenesis of the myelodysplastic syndromes. Eur J Hematol, 2015; 981: 3–15.

  4. Swerdlow SH, Campo E, et al eds: WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, IARC, 2017.

  5. 三谷絹子：急性骨髄性白血病の分子病態と分子標的療法．日本内科学会誌，2018; 107: 1648–1659.

  6. Dohner H, Weisdorf DJ, et al: Acute myeloid leukemia. New Engl J Med, 2015; 373; 1136–1152.

  7. Papaemmanuil E, Gerstung M, et al: Genomic classification and prognosis in acute myeloid leukemia. N Engl J Med, 2016; 374: 2209–2221.

  8. Naoe T, Kiyoi H: Gene mutations of acute myeloid leukemia in the genome era. Int J Hematol, 2013; 97: 165–174.

  9. 宮本敏浩：白血病幹細胞．日本内科学会誌，2013; 102: 1652–1660.

  10. Gilliland DG, Tallman MS: Focus on acute leukemias. Cancer Cell, 2002; 1: 417–420.

  11. Abdel-Wahab O, Levine R, et al: Mutations in epigenetic modifiers in the pathogenesis and therapy of acute myeloid leukemia. Blood, 2013; 121: 3563–3572.

  12. 三谷絹子：発症機構とエピジェネティクス異常．造血器腫瘍とエピジェネティクス：治療への応用と新たな展開 (木崎昌弘編)，医薬ジャーナル社，2012; 83–95.

  13. Sirulnik A, Melnick A: Molecular pathogenesis of acute promyelocytic leukaemia and APL variants. Best Pract Res Clin Haemato, 2003; 16: 387–408.

  14. 石川裕一：CBF-AMLの分子病態と治療．臨床血液，2018: 59: 1997–2006.

  15. Winters AC, Bernt KM: MLL–rearranged leukemias—an update on science and clinical approaches. Front Pediatr, 2017; 5: 4.

  16. Pulikkan JA, Tenen DG, et al: C/EBPα deregulation as a paradigm for leukemogenesis. Leukemia, 2017; 31: 2279–2285.

  17. Falini B, Nicoletti I, et al: Acute myeloid leukemia carrying cytoplasmic/mutated nucleophosmin (NPMc+ AML): biologic and clinical features. Blood, 2007; 109: 874–885.

  18. Apperley JF: Chronic myeloid leukaemia. Lancet, 2014; 385: 1447–1459.

  19. Ciboddo M, Mullally A: JAK2 (and other genes) be nimble with MPN diagnosis, prognosis, and therapy. Hematology Am Soc Hematol Educ Program, 2018; 2018: 110–117.

  20. Ogawa S: Gemetics of MDS. Blood, 2019; 133: 1049–1059.

  21. Lee JH, List A, et al: Molecular pathogenesis of myelodysplastic syndromes with deletion 5q. Eur J Haematol, 2019; 102: 203–209.

  22. Inaba H, Greaves M, et al: Acute lymphoblastic leukaemia. Lancet, 2013; 381: 1943–1955.

  23. Roberts KG: Genetics and prognosis of ALL in children vs adults. Hematology Am Soc Hematol Educ Program, 2018; 2018: 137–145.

  24. Rosenthal A, Rimsza L: Genomics of aggressive B–cell lymphoma. Hematology Am Soc Hematol Educ Program, 2018; 2018: 69–74.

  25. Jacobsen ED, Weinstock DM: Challenges and implications of genomics for T–cell Lymphomas. Hematology Am Soc Hematol Educ Program, 2018; 2018: 63–68.

  26. Furukawa Y, Kikuchi J: Molecular pathogenesis of multiple myeloma. Int J Clin Oncol, 2015; 20: 413–422.